WASHINGTON — The Food and Drug Administration on Friday approved a new drug from Roche to help treat patients with a type of cancer of the blood and bone marrow.
The agency cleared Gazyva to fight chronic lymphocytic leukemia in combination with chemotherapy in patients who haven’t previously been treated for the disease.
Gazyva works by killing cancer cells and encouraging the immune system to fight against them.
Chronic lymphocytic leukemia develops slowly over time and is usually diagnosed in the elderly.
The FDA approved the drug based on a study showing Gazyva plus chemotherapy was superior to chemotherapy alone at slowing the progress of the disease. Full story for BostonGlobe.com subscribers.